Table 1 Clinical characteristics of healthy controls and asthmatic children before inhaled corticosteroid therapy showing mild, moderate and severe persistent asthma
Parameters | Normal control | Mild persistent asthma | Moderate persistent asthma | Severe persistent asthma | Test p |
|---|---|---|---|---|---|
Number | 21/78 | 24/58 (41.3%) | 20/58 (34.5%) | 14/58 (24.1%) | |
Gender (boys/girls) | 9/12 | 13/11 | 12/8 | 6/8 | Chi-square p=0.64 |
Age (years) (mean±SD) | 10.7±2.1 | 6.32±2.99 | 9.22±3.33 | 7.24±3.53 | ANOVA* p<0.05 |
Total leukocytes | 7390 | 9720 | 8120 | 8305 | Kruskal-Wallis p=0.05 |
Neutrophils | 3440 | 4150 | 3640 | 4260 | Kruskal-Wallis p=0.66 |
Monocytes | 568 | 568 | 536 | 643 | Kruskal-Wallis p=0.57 |
Eosinophils | 245 | 460 | 635 | 487 | ANOVA p=0.003 |
BMI (Kg/m2) (mean±SD) | 43.31±32.1 | 51.9±34.2 | 47.4±31.2 | 63.7±32.5 | Kruskal-Wallis p=0.29 |
PEF (%) (mean±SD) | 86.9±18.6 | 81.2±17.3 | 75.6±15.3 | 65.6±12.0 | ANOVA** p<0.05 |
Treatment*** | |||||
ICS (%) | 23/23 (100%) | 10/20 (50%) | 05/14 (35.7%) | ||
ICS + LABA (%) | |||||
Budesonide + formoterol | 0/23 (0%) | 08/20 (40%) | 04/14 (28.6%) | ||
Fluticasone propionate + salmeterol | 0/23 (0%) | 02/20 (10%) | 05/14 (35.7%) |